More recently, CEAs have enabled epithelial gene therapy in patients with junctional epidermolysis bullosa (JEB), a blistering disease in which epithelia are inadequately anchored to the basement membrane owing to mutations in genes encoding laminin 332 (LAMA3, LAMB3, and LAMC2). This evidence concerns the gene LAMA3 and junctional epidermolysis bullosa.